Verified call record已核验电话会记录 · 2026-07-30

ALNY · ALNYLAM PHARMACE Q2 FY2026 earnings call record财报电话会记录

Verbatim, receipt-bound excerpts from the earnings-call transcript. This is a source record, not a synthesized analysis or recommendation.来自财报电话会文字记录的原文、可追溯摘录。这是来源记录，不是综合分析或推荐。

Continue in Terminal在终端继续研究ALNY

12 exact excerpts 条原文摘录 29 numeric receipts 个数值回执 B governed source tier 治理来源层级 Transcript present电话会文本已具备

The record记录内容

Call language, kept intact.电话会表述，保持原貌。

The excerpts below are selected from the source record under the bounded evidence policy. Wording is not paraphrased; numbers remain the exact spans captured from the call.以下摘录按受限证据策略从来源记录中选出。文字未被改写；数字保持电话会中捕获的精确片段。

guidanceperformancerisksq_and_a

“We are also updating our guidance for collaboration and royalty revenues to a revised range of $575 million-$625 million, representing a $150 million increase at the midpoint of the range, driven primarily by strong performance of LEQVIO and the resulting royalties from Novartis, as well as higher cost reimbursement from Roche favorably impacting collaboration revenue, driven by the pace of enrollment in our ZENITH phase III study with zilebesiran.”

Jeff Poulton · CFOclaim_c8995ac0fe265047a09953f55cf89a25

Exact numeric spans精确数值片段575 million625 million150 million

guidanceperformanceq_and_a

“As Yvonne noted, we are revising our total net product revenue guidance to $4.7 billion-$5.1 billion, driven fully by an update of our TTR revenue guidance to $4.2 billion-$4.5 billion, representing a $200 million reduction from our original TTR guidance at the midpoint and still reflects a robust 75% growth year-over-year.”

Jeff Poulton · CFOclaim_d4a84a1b0efd939405ec9d7c32471146

Exact numeric spans精确数值片段4.7 billion5.1 billion4.2 billion4.5 billion200 million75%

Member evidence layer会员证据层

10 more verified excerpts continue below.条更多已核验摘录在下方继续。

You have the public source preview. Essential and Pro unlock the complete call record, every remaining numeric receipt, and the full audit table—without replacing source language with generated opinion.你正在阅读公开来源预览。Essential 与 Pro 可解锁完整电话会记录、全部剩余数值回执和完整审计表——不会用生成式观点替代来源原文。

Unlock full company intelligence解锁完整公司情报

2 public excerpts 条公开摘录10 member excerpts 条会员摘录29 total numeric receipts 个数值回执

Inspect the source receipts检查来源回执41 bound spans个已绑定片段

Each available row identifies the source body, transcript segment and byte span used to verify the visible text.每个可用行都标识用于核验可见文本的来源正文、电话会片段和字节范围。

Claim主张	Kind类型	Segment片段	Byte span字节范围	Text hash文本哈希
`claim_d4a84a1b0efd939405ec9d7c32471146`	quote	13	137–462	`d0304bea7214e2…`
`claim_ec63def85c2dc7d014e55f3c0047741b`	numeric	13	213–224	`f578526a4da164…`
`claim_8e4cc0e576a7a6f40c9c6bdbefab10ed`	numeric	13	226–237	`1ed36d3cded2c4…`
`claim_89e038aa3352234f57ff7911c2f995fe`	numeric	13	297–308	`cb6a9c3319a51f…`
`claim_ffabc54c1381d0f8cd8da2517609e7a5`	numeric	13	310–321	`8ba1a53d70abc9…`
`claim_a434e7fed11b777d97d79a71b5506265`	numeric	13	339–350	`e73ab220e8f141…`
`claim_9388f0e2864466115d203acbceb98c5e`	numeric	13	436–439	`10963ac2db22b5…`
`claim_c8995ac0fe265047a09953f55cf89a25`	quote	16	0–452	`d06bc68f137187…`
`claim_faf503e85aa0c84c015c40487ceb50a7`	numeric	16	96–107	`1a473963bc33cd…`
`claim_d5b655953f0dc8c2fc753fac60ff91b2`	numeric	16	109–120	`416ed0c7c686bc…`
`claim_bcb7d2ed57e7a7b4de457c623b7fd7d0`	numeric	16	138–149	`becafac50d1703…`